By Ahmed Aboulenein WASHINGTON, Dec 18 (Reuters) - Americans enrolled in Medicare will pay about 50% less out of pocket in ...
Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...
Nxera Pharma, which recently announced a number of job cuts in Cambridge, is putting on a brave face after suffering another ...
Numab to receive milestone payment Boehringer Ingelheim has advanced its novel multi-specific antibody for retinal diseases resulting from a collaboration with Numab into preclinical development ...
Boehringer Ingelheim launched the first-ever Catvocacy Forum for the company, uniting veterinarians to elevate cat care ...
Galux signed a research agreement with Boehringer Ingelheim to advance AI-driven precision protein design for next-generation ...
AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon to announce agreements ...
Pets Date Night, Boehringer Ingelheim’s signature event, celebrates the special bond between pets and their families and ...
Galux has signed a research agreement with Boehringer Ingelheim to jointly explore the application of AI in precision protein ...
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer ...
A generic product for managing pain and inflammation associated with osteoarthritis (OA) in canines has been approved by FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback